Publikationen
Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan Andreas Keil, Sean R. Hall, Meike Körner, Martin Herrmann, Ralph A. Schmid and Steffen Frese Arthritis Research & Therapy, 2016 Oct 22. 18(1): 243 DOI: 10.1186/s13075-016-1144-5 – http://www.ncbi.nlm.nih.gov/pubmed/27770825
The topoisomerase I inhibitor irinotecan and the tyrosyl-DNA phosphodiesterase 1 inhibitor furamidine synergistically suppress murine lupus nephritis Andreas Keil, Manuela Frese-Schaper, Selina K. Steiner, Meike Körner, Ralph A. Schmid and Steffen Frese Arthritis & Rheumatology, 2015 Mar 16. doi: 10.1002/art.39119 – http://www.ncbi.nlm.nih.gov/pubmed/25779651
Low-Dose Irinotecan Improves Advanced Lupus Nephritis in MicePotentially by Changing DNA Relaxation and Anti–Double–Stranded DNA Binding Manuela Frese-Schaper, Andreas Keil, Selina K. Steiner, Mathias Gugger, Meike Körner, Gregor J. Kocher, Lena Schiffer, Hans-Joachim Anders, Uyen Huynh-Do, Ralph A. Schmid and Steffen Frese. Arthritis & Rheumatology, Vol. 66, No. 8, August 2014, pp 2259–2269, DOI 10.1002/art.38665 – www.ncbi.nlm.nih.gov/pubmed/24729466, Supplement
Structural modification of DNA – a therapeutic option in SLE? Steffen Frese and Betty Diamond. Nature Reviews Rheumatology, Volume 7, Dec 2011 - http://www.ncbi.nlm.nih.gov/pubmed/22009329
Reversal of Established Lupus Nephritis and Prolonged Survival of New Zealand Black x New Zealand White Mice Treated with the Topoisomerase I Inhibitor Irinotecan, Manuela Frese-Schaper, Jakob Zbaeren, Mathias Gugger,† Marc Monestier,‡ and Steffen Frese. The Journal of Immunology, February 15, 2010 Vol. 184 No. 4 2175-2182, DOI: 10.4049/jimmunol.0903153 – http://www.ncbi.nlm.nih.gov/pubmed/20083657